导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 7.26% | 904/4773 |
| 近一周 | -2.66% | 2779/5462 |
| 近一月 | -5.14% | 3077/5421 |
| 近一季 | -8.92% | 3018/5209 |
| 近半年 | -2.08% | 1770/4920 |
| 近一年 | 10.96% | 944/4366 |
| 近两年 | 62.51% | 1139/2954 |
| 近三年 | 26.75% | 1195/2253 |
| 成立以来 | 37.27% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
3.15% 797/4961 |
24.77% 1055/5312 |
- - |
- - |
| 2025 | 23.13% 1904/4813 |
1.91% 1519/3635 |
4.12% 856/4076 |
13.35% 3008/4524 |
2.39% 969/4813 |
| 2024 | 3.84% 1906/3463 |
-2.34% 1350/2808 |
-3.32% 1344/3014 |
11.10% 2557/3129 |
-1.01% 1564/3463 |
| 2023 | -13.57% 1554/2656 |
2.35% 1365/2280 |
-4.39% 1156/2385 |
-4.46% 1146/2515 |
-7.56% 2170/2655 |
| 2022 | -20.05% 926/2207 |
-15.74% 1065/1919 |
4.16% 1051/2016 |
-9.74% 303/2113 |
0.93% 1425/2208 |
| 2021 | 16.19% 277/1822 |
-3.80% 826/1255 |
11.02% 407/1330 |
3.97% 389/1466 |
4.63% 322/1822 |
| 2020 | - - |
- - |
- - |
8.22% 726/1164 |
5.10% 806/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 平安中证500指数增强C VS. 长安沪深300非周期A(740101) |